Palvella Therapeutics (PVLA) Revenue (2014 - 2024)
Palvella Therapeutics (PVLA) posted quarterly Revenue of $53000.0 for Q1 2024, down 97.36% year-over-year from $2.0 million in Q2 2023, and up 101.89% quarter-over-quarter from -$2.8 million in Q4 2023.
Palvella Therapeutics (PVLA) Revenue (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Revenue for 11 consecutive years, with $53000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Revenue fell 97.36% year-over-year to $53000.0; the TTM figure through Sep 2024 stood at -$2.7 million (down 106.58% YoY), while the FY2023 annual figure was $38.7 million, up 8840.18% from the prior year.
- Revenue improved to $53000.0 in Q1 2024 per PVLA's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Revenue topped out at $20.1 million in Q2 2023 and bottomed at -$3.5 million in Q4 2020.
- Historically, Revenue has averaged $5.9 million across 5 years, with a median of $2.6 million in 2020.
- On a YoY basis, Revenue climbed as much as 8619.57% in 2023 and fell as far as 2143.8% in 2023.
- Palvella Therapeutics' Revenue stood at -$3.5 million in 2020, then jumped by 338.84% to $8.4 million in 2021, then plunged by 98.38% to $137000.0 in 2022, then slumped by 2143.8% to -$2.8 million in 2023, then jumped by 101.89% to $53000.0 in 2024.
- Business Quant data shows PVLA's Revenue at $53000.0 in Q1 2024, -$2.8 million in Q4 2023, and $19.5 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | -2.80 Mn |
| Sep 30, 2023 | 19.52 Mn |
| Jun 30, 2023 | 20.06 Mn |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 137,000.00 |
| Sep 30, 2022 | 258,000.00 |
| Jun 30, 2022 | 230,000.00 |
| Mar 31, 2022 | 10.99 Mn |
| Dec 31, 2021 | 8.44 Mn |
| Sep 30, 2021 | 4.06 Mn |
| Jun 30, 2021 | 745,000.00 |
| Mar 31, 2021 | 13.00 Mn |
| Dec 31, 2020 | -3.54 Mn |
| Sep 30, 2020 | 2.58 Mn |
| Jun 30, 2020 | 10.93 Mn |
| Mar 31, 2020 | 13.26 Mn |
| Dec 31, 2019 | 17.27 Mn |
| Sep 30, 2019 | 15.13 Mn |
| Jun 30, 2019 | 5.33 Mn |